Pharmacokinetic, pharmacodynamic, and outcome investigations as the basis for mycophenolic acid therapeutic drug monitoring in renal and heart transplant patients

Clinical Biochemistry

Volumn 34, Issue 1, 2001, Pages 17-22

  Shaw, Leslie M ^a   Korecka, Magdalena ^a,b   DeNofrio, David ^a,b   Brayman, Kenneth L ^a,b  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; INOSINATE DEHYDROGENASE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ANTIGEN EXPRESSION; AREA UNDER THE CURVE; CLINICAL TRIAL; CONFERENCE PAPER; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG WITHDRAWAL; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; PROPHYLAXIS; RISK; STEADY STATE;

AREA UNDER CURVE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MYCOPHENOLIC ACID; TIME FACTORS; TREATMENT OUTCOME;

EID: 0035116884     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9120(00)00184-3     Document Type: Conference Paper

References (37)

1. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients, the US Renal Transplant Mycophenolate Mofetil Study Group
2. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection
3. A blinded randomized clinical trial of mycophenolate mofetil for the prevention of cadaveric renal transplantation
4. Immunologic factors: The major risk for decreased long-term renal allograft survival
5. Immunologic and nonimmunologic factors. Different risks for cadaver and living donor transplantation
6. Mycophenolate mofetil in renal allograft recipients: A pooled efficacy analysis of three randomized double-blind, clinical studies in prevention of rejection
7. Mycophenolate mofetil decreases renal allograft loss independent of acute rejection
8. Mycophenolate mofetil improves early steroid withdrawal in orthotopic heart transplant recipients
9. Clinical pharmacokinetics of mycophenolate mofetil
10. Identification of glucoside and carboxy-linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil
11. Structure and mechanism of inosine monophosphate dehydrogenase in complex with the immunosuppressant mycophenolic acid
12. Induction of cytokine release by the acyl glucuronide of mycophenolic acid: A link to side effects?
13. Pharmacokinetics of mycophenolate mofetil: A short review
14. Reduction of plasma mycophenolic acid and its glucuronide concentrations with antibiotic treatment
15. Intravenous mycophenolate mofetil (MMF): Safety, tolerability, and pharmacokinetics
16. Mycophenolic acid area under the curve values in African Am and Caucasian renal transplant patients are comparable
17. Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients
18. Pharmacokinetics and concentration-control investigations of mycophenolic acid in adults after transplantation
19. Coadministration of tacrolimus (FK) and mycophenolate mofetil (MMF) does not increase mycophenolic acid exposure, but coadministration of cyclosporine (CsA) and MMF inhibits the enterohepatic recirculation of MPA, thereby decreasing its exposure
20. Effect of cyclosporine on mycophenolic acid trough levels in kidney transplant recipients
21. Mycophenolic acid binding to human serum albumin: Characterization and relation to pharmacodynamics
22. Pharmacokinetics of mycophenolic acid in renal transplant patients with delayed graft function
23. The effect of renal insufficiency on mycophenolic acid protein binding
24. Pharmacokinetics of mycophenolic acid in renal insufficiency
25. Effect of initial slow graft function on renal allograft rejection and survival
26. Does plasma protein binding of mycophenolic acid affect its clearance?
27. Pharmacodynamics of immunosuppression by mycophenolic acid: Inhibition of both lymphocyte proliferation and activation correlates with pharmacokineitcs
28. Pharmacodynamics of mycophenolic acid in heart transplant recipients: Correlation of lymphocyte proliferation and activation with pharmacokinetics and graft histology
29. The pharmacokineitc-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation
30. Pilot study of mycophenolate mofetil in the prevention of acute rejection folowing renal transplantation in Japanese patients
31. Mycophenolic acid concentrations are associated with cardiac allograft rejection
32. Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: Implications for therapeutic drug monitoring
33. Pharmacokinetic-pharmacodynamic relationship for mycophenolic acid in renal transplant patients
34. Decreased protein binding of mycophenolic acid associated with leukopenia in a pancreas transpalnt recipient with renal failure
35. Combination therapy with tacrolimus and mycophenolate mofetil following cardiac transplantation: Importance of mycophenolic acid therapeutic drug monitoring
36. Relationship of mycophenolic acid area under the concentration-time curve and post-dose mycophenolic acid levels in heart transplant patients